Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.
Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.
Dodick
David W
DW
Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA. Dodick.David@mayo.edu
Lipton
Richard B
RB
Ferrari
Michel D
MD
Goadsby
Peter J
PJ
McCrory
Douglas
D
Cutrer
F Michael
FM
Williams
Paul
P
D000818:Animals; D003625:Data Collection; D003661:Decision Support Techniques; D006801:Humans; D015201:Meta-Analysis as Topic; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology; D009462:Neurology; D010820:Physicians; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
D017366:Serotonin Receptor Agonists